Pfizer.com receives first makeover in three years

Share this article:
Pfizer has launched a refreshed consumer Web site featuring a cleaner design and new features.

“I think the site is warmer and more emotional in tone than the previous one, and it's reflective of what we've heard from our survey (of users),” Pfizer spokesman Andy McCormick told MM&M.
For Pfizer.com's first Web site makeover in nearly three years, the company worked with Grey unit G2 Direct and Digital to incorporate a product search on every single page.

“We've made it easier for our users to access our updated product information,” Pfizer spokeswoman Kate Bird added. “We've also incorporated a technology called Ajax, which is a combination of JavaScript and XML. That gives us the opportunity to highlight and promote certain events and programs without taking the user several clicks into the site.”

Other new Pfizer.com features include automated Securities and Exchange Commission filings and a more robust investor dashboard for Pfizer's investor population.

Also, a new R&D section features information on Pfizer's product pipeline as well as post-marketing commitments that are updated on a weekly basis.

Pfizer.com averages about 4 million visitors per year. That audience is comprised of both consumers and healthcare professionals, according to Bird.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.